货号:A374780
同义名:
多替拉韦
/ S/GSK1349572; GSK1349572
Dolutegravir is an integrase inhibitor (IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Dolutegravir is a highly potent and orally bioavailable inhibitor of HIV integrase strand transfer, with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. It effectively inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir also maintains significant potency against HIV-1 mutants Y143R, N155H, and G140S/Q148H (EC50=3.6-5.8 nM)[1][2]. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活性说明 | 数据源 |
MDCK2 cells | Function assay | Inhibition of human OCT2 expressed in MDCK2 cells using [14C]metformin as substrate by liquid scintillation counting analysis | 23132334 |
Animal study | After a single intravenous (IV) dose of Dolutegravir, plasma clearance is low in rats (0.23 mL/min/kg) and monkeys (2.12 mL/min/kg). The half-lives in rats and monkeys are similar, approximately 6 hours, and the steady-state volume of distribution (VSS) is low. Upon oral administration, Dolutegravir is rapidly absorbed with high oral bioavailability when administered as a solution to fasted male rats and a single monkey (75.6% and 87.0%, respectively). Dolutegravir exposure (Cmax and AUC) increases with dose escalation following oral administration of a suspension to non-fasted rats up to 250 mg/kg and non-fasted monkeys up to 50 mg/kg, although the increase is less than proportional[3]. | |||||||||||||||||||||||||||||||||
Pharmacokinetics |
|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00867152 | Healthy Volunteer | Phase 1 | Completed | - | United States, New York ... 展开 >> GSK Investigational Site Buffalo, New York, United States, 14202 收起 << |
NCT00858455 | Healthy Volunteer | Phase 1 | Completed | - | United States, New York ... 展开 >> GSK Investigational Site Buffalo, New York, United States, 14202 收起 << |
NCT01302847 | HIV Infections | Phase 1 Phase 2 | Recruiting | June 30, 2023 | - |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.38mL 0.48mL 0.24mL |
11.92mL 2.38mL 1.19mL |
23.84mL 4.77mL 2.38mL |
CAS号 | 1051375-16-6 |
分子式 | C20H19F2N3O5 |
分子量 | 419.38 |
SMILES Code | O=C(C1=CN(C2=C(O)C1=O)C[C@]3([H])OCC[C@@H](C)N3C2=O)NCC4=CC=C(F)C=C4F |
MDL No. | MFCD20488027 |
别名 | 多替拉韦 ;S/GSK1349572; GSK1349572 |
运输 | 蓝冰 |
InChI Key | RHWKPHLQXYSBKR-BMIGLBTASA-N |
Pubchem ID | 54726191 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, 2-8°C |
动物实验配方 |
IP 2% DMSO+2% Tween80+40% PEG300+water 2 mg/mL clear PO 0.5% CMC-Na 70 mg/mL suspension |